| MeSH term | MeSH ID | Detail |
|---|---|---|
| Fractures, Bone | D050723 | 4 associated lipids |
| Renal Insufficiency, Chronic | D051436 | 9 associated lipids |
| Hypercalciuria | D053565 | 4 associated lipids |
| Acute Coronary Syndrome | D054058 | 11 associated lipids |
| No-Reflow Phenomenon | D054318 | 2 associated lipids |
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | D054438 | 1 associated lipids |
| Hyperphosphatemia | D054559 | 1 associated lipids |
| Osteophyte | D054850 | 2 associated lipids |
| Chronic Periodontitis | D055113 | 1 associated lipids |
| Primary Myelofibrosis | D055728 | 6 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Bénard J | [From metastatic osteolysis a painful message: beginning to understand with osteoprotegerin? | 2000 | Bull Cancer | pmid:11184451 |
| Yamashita T et al. | Retardation in bone resorption after bone marrow ablation in klotho mutant mice. | 2000 | Endocrinology | pmid:10614667 |
| Hofbauer LC et al. | The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. | 2000 | J. Bone Miner. Res. | pmid:10646108 |
| Kanzawa M et al. | Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. | 2000 | Eur. J. Endocrinol. | pmid:10822231 |
| Mukohyama H et al. | The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10777696 |
| Atkins GJ et al. | Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. | 2000 | J. Bone Miner. Res. | pmid:10780856 |
| Thompson SW and Tonge D | Bone cancer gain without the pain. | 2000 | Nat. Med. | pmid:10802700 |
| Honore P et al. | Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. | 2000 | Nat. Med. | pmid:10802707 |
| Onyia JE et al. | In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. | 2000 | J. Bone Miner. Res. | pmid:10804015 |
| Bateman TA et al. | Osteoprotegerin mitigates tail suspension-induced osteopenia. | 2000 | Bone | pmid:10773583 |
| Malyankar UM et al. | Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. | 2000 | J. Biol. Chem. | pmid:10811631 |
| Thirunavukkarasu K et al. | The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. | 2000 | J. Biol. Chem. | pmid:10833509 |
| Aubin JE and Bonnelye E | Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. | 2000 | Medscape Womens Health | pmid:10792853 |
| Fata JE et al. | The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. | 2000 | Cell | pmid:11051546 |
| Kong YY et al. | Osteoprotegerin ligand: a regulator of immune responses and bone physiology. | 2000 | Immunol. Today | pmid:11071528 |
| Kobayashi Y et al. | Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor beta and osteoprotegerin expression. | 2000 | J. Bone Miner. Res. | pmid:11028444 |
| Kaneda T et al. | Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor. | 2000 | J. Immunol. | pmid:11035059 |
| Miyamoto T et al. | An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand. | 2000 | Blood | pmid:11110710 |
| Proposed standard nomenclature for new tumor necrosis factor members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. | 2000 | Bone | pmid:11113385 | |
| Takayanagi H et al. | T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. | 2000 | Nature | pmid:11117749 |
| Mancini L et al. | Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin. | 2000 | Biochem. Biophys. Res. Commun. | pmid:11118297 |
| Lee ZH et al. | Activation of c-Jun N-terminal kinase and activator protein 1 by receptor activator of nuclear factor kappaB. | 2000 | Mol. Pharmacol. | pmid:11093794 |
| Kong YY and Penninger JM | Molecular control of bone remodeling and osteoporosis. | 2000 | Exp. Gerontol. | pmid:11121682 |
| Shalhoub V et al. | Characterization of osteoclast precursors in human blood. | 2000 | Br. J. Haematol. | pmid:11122091 |
| Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. | 2000 | J. Bone Miner. Res. | pmid:11127193 | |
| Sakuma Y et al. | Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. | 2000 | Infect. Immun. | pmid:11083800 |
| Riggs BL | The mechanisms of estrogen regulation of bone resorption. | 2000 | J. Clin. Invest. | pmid:11086020 |
| Udagawa N et al. | Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. | 2000 | Endocrinology | pmid:10965921 |
| Yasuda H | [A new paradigm of osteoclast biology: discovery of OCIF and ODF]. | 2000 | Seikagaku | pmid:10967683 |
| Teitelbaum SL | Bone resorption by osteoclasts. | 2000 | Science | pmid:10968780 |
| Lacey DL et al. | Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. | 2000 | Am. J. Pathol. | pmid:10934148 |
| Quinn JM et al. | Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. | 2000 | J. Bone Miner. Res. | pmid:10934644 |
| Min H et al. | Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. | 2000 | J. Exp. Med. | pmid:10952716 |
| Shiba H et al. | Effects of ageing on proliferative ability, and the expressions of secreted protein, acidic and rich in cysteine (SPARC) and osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human periodontal ligament cells. | 2000 | Mech. Ageing Dev. | pmid:10958924 |
| López FJ | New approaches to the treatment of osteoporosis. | 2000 | Curr Opin Chem Biol | pmid:10959765 |
| Nakashima T et al. | Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10973797 |
| Itoh K et al. | Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. | 2000 | J. Bone Miner. Res. | pmid:10976996 |
| Schinke T and Karsenty G | Vascular calcification--a passive process in need of inhibitors. | 2000 | Nephrol. Dial. Transplant. | pmid:10978374 |
| Lorenzo J | Interactions between immune and bone cells: new insights with many remaining questions. | 2000 | J. Clin. Invest. | pmid:10995785 |
| Teng YT et al. | Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. | 2000 | J. Clin. Invest. | pmid:10995794 |
| Børset M et al. | Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. | 2000 | Blood | pmid:11001907 |
| Tsurukai T et al. | Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis. | 2000 | J. Bone Miner. Metab. | pmid:10874596 |
| Günther T and Schinke T | Mouse genetics have uncovered new paradigms in bone biology. | 2000 | Trends Endocrinol. Metab. | pmid:10856921 |
| Huang L et al. | Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. | 2000 | Am. J. Pathol. | pmid:10702390 |
| Capparelli C et al. | Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. | 2000 | Cancer Res. | pmid:10706080 |
| Makhluf HA et al. | Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10679262 |
| Merewether LA et al. | Development of disulfide peptide mapping and determination of disulfide structure of recombinant human osteoprotegerin chimera produced in Escherichia coli. | 2000 | Arch. Biochem. Biophys. | pmid:10683254 |
| Ross FP | RANKing the importance of measles virus in Paget's disease. | 2000 | J. Clin. Invest. | pmid:10712423 |
| Tricot G | New insights into role of microenvironment in multiple myeloma. | 2000 | Lancet | pmid:10675068 |
| Takayanagi H et al. | Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. | 2000 | Arthritis Rheum. | pmid:10693864 |
| Itonaga I et al. | Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages. | 2000 | Ann. Rheum. Dis. | pmid:10627423 |
| Chikatsu N et al. | Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10631114 |
| Takami M et al. | Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. | 2000 | Endocrinology | pmid:11108286 |
| Gori F et al. | The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. | 2000 | Endocrinology | pmid:11108292 |
| Clohisy DR et al. | Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. | 2000 | J. Orthop. Res. | pmid:11192258 |
| Aubin JE and Bonnelye E | Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. | 2000 | Osteoporos Int | pmid:11193242 |
| Wise GE et al. | Osteoprotegerin and osteoclast differentiation factor in tooth eruption. | 2000 | J. Dent. Res. | pmid:11201042 |
| Kotake S et al. | [Molecular mechanism of bone metabolism]. | 2000 | Nippon Naika Gakkai Zasshi | pmid:11215116 |
| Kanematsu M et al. | [Clinostat rotation culture modulates gene expression of osteoclastogenesis-regulating factors via a cyclic-AMP dependent mechanism]. | 2000 | Biol. Sci. Space | pmid:12561872 |
| Fazzalari NL et al. | The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. | 2001 | J. Bone Miner. Res. | pmid:11393778 |
| Bekker PJ et al. | The effect of a single dose of osteoprotegerin in postmenopausal women. | 2001 | J. Bone Miner. Res. | pmid:11204435 |
| Kikuchi T et al. | Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. | 2001 | J. Immunol. | pmid:11207318 |
| O'Brien EA et al. | Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. | 2001 | Bone | pmid:11182380 |
| Zhang YH et al. | Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. | 2001 | J. Biol. Chem. | pmid:11032840 |
| Goltzman D | Osteolysis and cancer. | 2001 | J. Clin. Invest. | pmid:11375409 |
| Zhang J et al. | Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. | 2001 | J. Clin. Invest. | pmid:11375413 |
| Kostenuik PJ and Shalhoub V | Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. | 2001 | Curr. Pharm. Des. | pmid:11375772 |
| Takemura M et al. | Relationship between osteoprotegerin/osteoclastogenesis inhibitory factor concentration in synovial fluid and disease severity in individuals with osteoarthritis of the knee. | 2001 | Metab. Clin. Exp. | pmid:11172466 |
| Gravallese EM et al. | The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. | 2001 | Arthritis Res. | pmid:11178122 |
| Makiishi-Shimobayashi C et al. | Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11181055 |
| Lories RJ and Luyten FP | Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets. | 2001 | Clin. Rheumatol. | pmid:11254237 |
| Wan M et al. | Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegrin gene expression. | 2001 | J. Biol. Chem. | pmid:11139569 |
| Browner WS et al. | Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. | 2001 | J. Clin. Endocrinol. Metab. | pmid:11158021 |
| Hofbauer LC and Heufelder AE | [Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases]. | 2001 | Dtsch. Med. Wochenschr. | pmid:11233883 |
| Bolon B et al. | Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. | 2001 | Mol. Ther. | pmid:11237676 |
| Sasaki N et al. | Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. | 2001 | Nephrol. Dial. Transplant. | pmid:11239019 |
| Takeuchi T et al. | Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. | 2001 | Biochem. Pharmacol. | pmid:11239501 |
| Chikazu D et al. | Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. | 2001 | J. Bone Miner. Res. | pmid:11697804 |
| Khosla S | Minireview: the OPG/RANKL/RANK system. | 2001 | Endocrinology | pmid:11713196 |
| Seidel C et al. | Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. | 2001 | Blood | pmid:11568016 |
| Fukagawa M et al. | Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases. | 2001 | Am. J. Kidney Dis. | pmid:11576943 |
| Sato T et al. | Osteoprotegerin levels before and after renal transplantation. | 2001 | Am. J. Kidney Dis. | pmid:11576949 |
| Feuerherm AJ et al. | Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. | 2001 | Scand. J. Rheumatol. | pmid:11578019 |
| Sakai E et al. | Characterization of phagosomal subpopulations along endocytic routes in osteoclasts and macrophages. | 2001 | J. Biochem. | pmid:11726283 |
| Quinn JM et al. | Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. | 2001 | J. Bone Miner. Res. | pmid:11585342 |
| Choi SJ et al. | Osteoclast inhibitory peptide 2 inhibits osteoclast formation via its C-terminal fragment. | 2001 | J. Bone Miner. Res. | pmid:11585344 |
| Miyamoto T et al. | Bifurcation of osteoclasts and dendritic cells from common progenitors. | 2001 | Blood | pmid:11588053 |
| Pearse RN et al. | Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11562486 |
| Feige U | Osteoprotegerin. | 2001 | Ann. Rheum. Dis. | pmid:11890662 |
| Yano K et al. | Synovial cells from a patient with rheumatoid arthritis produce osteoclastogenesis inhibitory factor/osteoprotegerin: reciprocal regulation of the production by inflammatory cytokines and basic fibroblast growth factor. | 2001 | J. Bone Miner. Metab. | pmid:11685652 |
| Kawahara N et al. | Two novel cucurbitacins, neocucurbitacins A and B, from the Brazilian folk medicine "Buchinha" (Luffa operculata) and their effect on PEBP2alphaA and OCIF gene expression in a human osteoblast-like Saos-2 cell line. | 2001 | Chem. Pharm. Bull. | pmid:11605678 |
| Boissy P et al. | RANKL induces formation of avian osteoclasts from macrophages but not from macrophage polykaryons. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11606048 |
| Wise GE et al. | Effects of dexamethasone on tooth eruption in rats: differences in incisor and molar eruption. | 2001 | Clin Anat | pmid:11301468 |
| Atkins GJ et al. | Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. | 2001 | Bone | pmid:11336917 |
| Komine M et al. | Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. | 2001 | Bone | pmid:11344046 |
| Chen D et al. | ELISA methodology for detection of modified osteoprotegerin in clinical studies. | 2001 | Clin. Chem. | pmid:11274028 |
| Collin-Osdoby P et al. | Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. | 2001 | J. Biol. Chem. | pmid:11274143 |
| Brown JM et al. | Osteoprotegerin and rank ligand expression in prostate cancer. | 2001 | Urology | pmid:11306358 |
| Fukagawa M et al. | [PTH and bone metabolism in chronic dialysis patients]. | 2001 | Rinsho Byori | pmid:11307321 |
| Horowitz MC et al. | Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. | 2001 | Cytokine Growth Factor Rev. | pmid:11312114 |